Table 4 Factors associated with high SARS-CoV2-IgG spike antibody level
From: Impact of comorbidities on the serological response to COVID-19 vaccination in a Taiwanese cohort
SARS-CoV-2 IgG titers ≧ 4160 AU/mL (n = 636) | SARS-CoV-2 IgG titers < 4160 AU/mL (n = 188) | P value | Logistic regression analysis | |||
|---|---|---|---|---|---|---|
OR | 95% CI | P value | ||||
Age ≧ 60 years, n (%) | 321 (50.5) | 113 (60.1) | 0.03 | 0.50 | 0.34–0.72 |  < 0.001 |
Female, n (%) | 348 (54.7) | 75 (39.9) |  < 0.001 | 1.85 | 1.30–2.63 | 0.001 |
BMI (kg/m2, mean (SD)) | 24.4 (3.9) | 24.0 (4.2) | 0.36 | |||
Medical history | ||||||
Dyslipidemia, n/N (%) | 98/635 (15.4) | 30/187 (16.0) | 0.84 | |||
Hypertension, n/N (%) | 211/635 (33.2) | 67/187 (35.8) | 0.51 | |||
Diabetes, n/N (%) | 101/635 (15.9) | 46/187 (24.6) | 0.01 | |||
Chronic kidney disease, n/N (%) | 109/635 (17.2) | 57/187 (30.5) |  < 0.001 | |||
HIV infection, n/N (%) | 3/635 (0.5) | 2/187 (1.1) | 0.32 | |||
Chronic liver disease, n/N (%) | 430/635 (67.7) | 122/187 (65.2) | 0.53 | |||
Cardiovascular disease, n/N (%) | 15/632 (2.4) | 2/186 (1.1) | 0.39 | |||
Cerebrovascular disease, n/N (%) | 6/632 (0.9) | 4/186 (2.2) | 0.25 | |||
COPD, n/N (%) | 10/632 (1.6) | 4/186 (2.2) | 0.53 | |||
History of malignancy, n/N (%) | 70/635 (11.0) | 31/187 (16.6) | 0.04 | |||
Vaccination type, the first 2 doses | ||||||
AZ–AZ | 326 (51.3) | 149 (79.3) | 1 | |||
Medigen–Medigen | 13 (2.0) | 7 (3.7) | 0.82 | 0.31–2.16 | 0.69 | |
BNT–BNT | 31 (4.9) | 2 (1.1) | 7.91 | 1.82–34.3 | 0.006 | |
Moderna–Moderna | 232 (36.5) | 21 (11.2) | 6.49 | 3.90–10.83 |  < 0.001 | |
CCI |  < 0.001 | |||||
< 4 | 552 (86.6) | 141 (75.0) | 1 | |||
≧ 4 | 84 (13.2) | 47 (25.0) | 0.53 | 0.34–0.82 | 0.004 | |